Novo’s wonderdrug Ozempic shakes up markets

Novo Nordisk said its diabetes drug Ozempic showed surprisingly early effectiveness in a kidney-failure study, sending shares of the world’s biggest dialysis providers tumbling.

An independent data monitoring committee recommended halting the study after finding that an interim analysis had already met pre-set criteria for efficacy, Novo said late on Tuesday. The Danish drugmaker will get full results of the study once the process of closing it is complete, expected by the first half of ...